First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation
Authors
Keywords
-
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-07-07
DOI
10.1007/s00432-020-03311-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Front-Line Therapy in Advanced Non–Small Cell Lung Cancer With Sensitive Epidermal Growth Factor Receptor Mutations: a Network Meta-Analysis
- (2020) Xu-Yuan Li et al. CLINICAL THERAPEUTICS
- Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer
- (2020) Kenan Zhou et al. MEDICINE
- NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
- (2020) Makoto Maemondo et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I/II study of osimertinib with bevacizumab in EGFR-mutated, T790M-positive patients with progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L)
- (2019) Hiroaki Akamatsu et al. Clinical Lung Cancer
- Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
- (2019) Haruhiro Saito et al. LANCET ONCOLOGY
- Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non–Small Cell Lung Cancer
- (2019) Thomas E. Stinchcombe et al. JAMA Oncology
- 1480OCTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC
- (2019) Q Zhou et al. ANNALS OF ONCOLOGY
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
- (2019) Suresh S. Ramalingam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Kazuhiko Nakagawa et al. LANCET ONCOLOGY
- Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
- (2018) Binghao Zhao et al. LUNG CANCER
- Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer
- (2018) Jean-Charles Soria et al. NEW ENGLAND JOURNAL OF MEDICINE
- Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study
- (2018) Hiroaki Akamatsu et al. Clinical Lung Cancer
- Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol
- (2018) Takashi Ninomiya et al. Clinical Lung Cancer
- Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR -Mutated Non–Small Cell Lung Cancer
- (2017) Emily Castellanos et al. Journal of Thoracic Oncology
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
- (2017) Rafael Rosell et al. Lancet Respiratory Medicine
- BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2016) Cesare Gridelli et al. Clinical Lung Cancer
- Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
- (2016) Shu Zhang et al. BMJ Open
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now